Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients
Open Access
- 21 May 2022
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (9) , 7281-7292
Abstract
Background and objective: Paclitaxel and doxorubicin are associated with neurotoxicity and cardiotoxicity respectively. This study aimed at investigating the role of alpha-lipoic acid (ALA) in counteracting paclitaxel-induced neuropathy and doxorubicin-associated cardiotoxicity in women with breast cancer. Patients and methods: This randomized double-blind placebo-controlled prospective study included 64 patients with breast cancer who were randomized into control group (n = 32) which received 4 cycles of doxorubicin plus cyclophosphamide (every 21 days) followed by weekly doses of paclitaxel for 12 weeks plus placebo tablets once daily and ALA group (n = 32) which received the same chemotherapeutic regimen plus ALA 600 once daily for 6 months. Patients were assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4.0) for grading of neuropathy and by 12-item neurotoxicity questionnaire (Ntx-12). The assessment included also echocardiography and evaluation of serum levels of brain natriuretic peptide (BNP), tumor necrosis factor-alpha (TNF-α), malondialdehyde (MDA), and neurotensin (NT). Data were analyzed by paired and unpaired t-test, Mann–Whitney U test, and chi-square test. Results: As compared to placebo, ALA provoked significant improvement in NCI-CTCAE neuropathy grading and Ntx-12 score after the end of 9th and 12th weeks of paclitaxel intake (p = 0.039, p = 0.039, p = 0.03, p = 0.004, respectively). At the end of the chemotherapy cycles, ALA resulted in significant decline in serum levels of BNP, TNF-α, MDA, and neurotensin (p < 0.05) as compared to baseline data and placebo. Conclusion: Alpha-lipoic acid may represent a promising adjuvant therapy to attenuate paclitaxel-associated neuropathy and doxorubicin-induced cardiotoxicity in women with breast cancer. Trial registration: ClinicalTrials.gov: NCT03908528.Keywords
Funding Information
- Damanhour University
This publication has 47 references indexed in Scilit:
- Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled TrialsInternational Journal of Endocrinology, 2012
- Cardiovascular effects of systemic cancer treatmentCancer Treatment Reviews, 2011
- α-Lipoic acid has anti-inflammatory and anti-oxidative properties: an experimental study in rats with carrageenan-induced acute and cotton pellet-induced chronic inflammationsBritish Journal of Nutrition, 2010
- Revisiting the ALA/N (α-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New CasesIntegrative Cancer Therapies, 2009
- Up‐regulation of matrix metalloproteinase‐3 in the dorsal root ganglion of rats with paclitaxel‐induced neuropathyCancer Science, 2008
- Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic PolyneuropathyDiabetes Care, 2006
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- ALPHA-LIPOIC ACID AMELIORATES MYOCARDIAL TOXICITY INDUCED BY DOXORUBICINPharmacological Research, 2002
- B-Type Natriuretic Peptide — A Window to the HeartNew England Journal of Medicine, 2002
- Paclitaxel in cancer therapyExpert Opinion on Pharmacotherapy, 2002